Details for Patent: 8,940,330
Which drugs does patent 8,940,330 protect, and when does it expire?
Patent 8,940,330 protects ZUBSOLV and is included in one NDA.
This patent has fifty-one patent family members in thirty-two countries.
Summary for Patent: 8,940,330
| Title: | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Andreas Fischer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Edenbridge Pharmaceuticals LLC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US14/127,470 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,940,330 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Composition; Process; Dosage form; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 8,940,330: Buprenorphine-Naloxone Sublingual Tablet Patent Scope and LandscapeUS Patent 8,940,330 protects a specific buprenorphine-naloxone sublingual tablet architecture and its dry-mixing manufacturing process. The core limitation is the physical separation of buprenorphine microparticles and citric-acid-containing particles, combined with a defined disintegrant system. The patent does not broadly cover every buprenorphine-naloxone dosage form, every sublingual formulation, or the active ingredients themselves. The patent is most relevant to generic developers pursuing tablet products that reproduce the particle arrangement, excipient selection, and manufacturing sequence claimed in the patent. It is less directly relevant to films, buccal systems, injectable products, oral solutions, or tablets using a materially different particle architecture. What patent protects US 8,940,330?US 8,940,330 is directed to pharmaceutical compositions containing buprenorphine and naloxone for sublingual administration. The issued claims cover both the finished tablet and a process for preparing it.
The claim structure is formulation-specific. It combines composition limitations with particle-level physical relationships that may require analysis of formulation manufacture and microscopic or analytical evidence, not only the product label. What does independent claim 1 require?Claim 1 contains several cumulative requirements. A product must satisfy all of them to fall within the literal scope of the claim. 1. A tablet suitable for sublingual administrationThe claim is limited to a tablet composition suitable for sublingual use. A dosage form designed only for swallowing, injection, transdermal delivery, or buccal delivery would not ordinarily satisfy this limitation without evidence that it is also suitable for sublingual administration. The claim does not specify:
The absence of those limitations gives the claim breadth within the defined particle system. 2. Buprenorphine microparticlesThe formulation must contain microparticles of buprenorphine or a pharmaceutically acceptable salt. The term “microparticles” is not limited in claim 1 to a particular mean diameter, but dependent claim 2 narrows the scope to particles having a weight-based mean diameter below about 15 micrometers. A formulation with larger buprenorphine particles may avoid claim 2 but could still fall within claim 1 if the particles qualify as microparticles under the patent’s construction and satisfy the remaining limitations. 3. Buprenorphine presented upon carrier particlesThe buprenorphine microparticles must be presented upon the surface of carrier particles. This is a particle-engineering limitation, not merely a requirement that buprenorphine and an excipient be present in the same blend. The relevant distinction is between:
The patent therefore creates potential process and product-characterization issues. A generic developer may need to determine whether its manufacturing process produces the claimed surface association even if its formulation development documents use different terminology. 4. Contact with citric-acid particlesThe buprenorphine microparticles must be in contact with particles comprising citric acid. Claim 1 expressly requires that buprenorphine and citric acid are not in the same particle. This creates a two-part structural limitation:
The claim does not require citric acid to be the carrier particle in every embodiment. Claim 6 creates that narrower embodiment by specifying that the citric-acid particles are presented and act as carrier particles. A formulation in which buprenorphine and citric acid are co-processed into a single composite particle may avoid the literal wording of claim 1, depending on the particle structure and claim construction. A formulation in which citric acid is separately granulated but later blended with buprenorphine may still present infringement risk if the resulting particles are in the required contact relationship. 5. NaloxoneThe tablet must contain a pharmacologically effective amount of naloxone or a pharmaceutically acceptable salt. The claim does not specify the amount or ratio. This is important because the patent is not limited to a single commercial strength. Both lower- and higher-dose buprenorphine-naloxone tablets could fall within the claim if they satisfy the particle and excipient limitations. 6. A specified disintegrantThe disintegrant must be selected from:
This is a closed Markush group. A tablet using another disintegrant, such as an unlisted cellulose derivative or starch system, may avoid literal infringement of this limitation. The doctrine of equivalents could still become relevant, but the closed list strengthens the importance of formulation selection. How do dependent claims narrow the patent scope?
Claims 2 through 7 are product claims. Claims 8 through 11 are process claims. A developer may therefore face risk from the finished tablet, the manufacturing process, or both. What formulations are protected by US 8,940,330?The highest-risk formulation is a sublingual tablet with the following profile:
A conventional sublingual tablet containing buprenorphine, naloxone, mannitol, citric acid, and a disintegrant is not automatically within the claim. The particle relationships and manufacturing steps matter. What formulation design-arounds are most relevant?Potential design-around strategies include:
These approaches do not automatically avoid claim 1. For example, changing the manufacturing process may avoid claims 8 through 11 while leaving the finished composition exposed under claim 1. When does US 8,940,330 lose exclusivity?The patent has a nominal expiration date of September 30, 2028, based on the underlying priority and patent-term framework. The patent was granted on February 3, 2015, but the grant date does not determine the expiration date for a modern US utility patent.
The patent does not protect buprenorphine or naloxone as active ingredients. After expiration, the specific formulation and process claims cease to provide ordinary patent exclusivity, but separate patents, regulatory exclusivity, trade secrets, manufacturing controls, or later-issued continuation patents may still affect market entry. What is the Orange Book status of US 8,940,330?The patent landscape for buprenorphine-naloxone products must be separated by dosage form and NDA. Suboxone sublingual tablets, Suboxone sublingual film, and competing products such as Zubsolv do not necessarily share the same Orange Book patent listings. For an ANDA applicant, the relevant questions are:
The Orange Book listing must be evaluated against the specific reference NDA and strength. FDA Orange Book data, rather than the patent document alone, determines whether a listed patent creates a certification obligation for a particular ANDA.[1] Which companies are challenging the patent?A Paragraph IV challenge requires a specific ANDA, reference product, patent listing, and certification record. Patent disputes involving Suboxone have included challenges to formulation and delivery-system patents, particularly patents relating to sublingual films and abuse-deterrent or dosage-form performance. The principal litigation risk under US 8,940,330 differs from film-patent litigation because this patent claims a tablet and a tablet manufacturing process. A company developing a sublingual film may face other Suboxone patents without practicing the tablet limitations in this patent. A complete freedom-to-operate assessment should therefore distinguish:
How does US 8,940,330 compare with the broader Suboxone patent estate?US 8,940,330 should be treated as one component of the buprenorphine-naloxone patent estate rather than as a complete monopoly over Suboxone.
The patent is strongest where a competitor copies the particle-engineered tablet platform. It is weaker as a barrier to alternative dosage forms and formulations that do not use the claimed citric-acid contact arrangement. What patent litigation affects generic launch risk?Generic launch risk has four principal components:
For this patent, technical litigation would likely focus on:
Analytical evidence may include particle-size distribution, scanning electron microscopy, elemental or chemical mapping, granule cross-sections, excipient distribution studies, batch records, and process validation documents. What is the biosimilar risk for US 8,940,330?There is no biosimilar pathway risk because buprenorphine and naloxone are small-molecule drugs. A competing product would generally proceed through an ANDA or, depending on its formulation and clinical profile, a 505(b)(2) application. The practical competition risk is therefore generic substitution, not biosimilar substitution. The key regulatory issue is whether the proposed product can demonstrate pharmaceutical equivalence and bioequivalence while avoiding or resolving the listed patent claims. What is the commercial exposure?US 8,940,330 has commercial relevance primarily for tablet products containing buprenorphine and naloxone. Its exposure is narrower than the entire Suboxone franchise because:
The value of the patent depends on the product’s remaining market share, the continuing commercial use of the tablet formulation, the availability of authorized generics, and the extent to which competing products can design around the particle arrangement. How strong is the patent estate?US 8,940,330 has moderate-to-strong formulation specificity. Its strengths are:
Its weaknesses are:
Key Takeaways
FAQsDoes US 8,940,330 cover Suboxone film?Not directly based on the issued claims provided. The claims require a tablet suitable for sublingual administration. Suboxone film products are assessed primarily against separate film and manufacturing patents. Can a generic use mannitol without infringing US 8,940,330?Yes, mannitol alone does not establish infringement. Risk depends on whether the product also contains the claimed buprenorphine microparticles, carrier-particle presentation, separate citric-acid particles, naloxone, and listed disintegrant. Does avoiding dry mixing eliminate infringement risk?It may reduce risk under claims 8 through 11, but it does not necessarily avoid claim 1. The finished composition can remain relevant even if it is manufactured through a different process. Is citric acid mandatory under claim 1?Yes. Claim 1 requires buprenorphine microparticles to be in contact with particles comprising citric acid. A formulation without citric acid should not satisfy that limitation literally. Does the patent cover all buprenorphine-naloxone tablets until 2028?No. The patent covers only tablets meeting the claim limitations. A tablet using a different particle architecture, different excipient system, or different manufacturing approach may fall outside the claims, subject to claim construction and potential equivalents theories. References
More… ↓ |
Drugs Protected by US Patent 8,940,330
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-006 | Oct 4, 2016 | RX | Yes | No | 8,940,330 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-001 | Jul 3, 2013 | RX | Yes | No | 8,940,330 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-005 | Jun 4, 2015 | RX | Yes | No | 8,940,330 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,940,330
| PCT Information | |||
| PCT Filed | September 18, 2012 | PCT Application Number: | PCT/GB2012/052303 |
| PCT Publication Date: | March 28, 2013 | PCT Publication Number: | WO2013/041851 |
International Family Members for US Patent 8,940,330
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2012311293 | ⤷ Start Trial | |||
| Australia | 2013245546 | ⤷ Start Trial | |||
| Brazil | 112014006356 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
